From the other board:

New Post Public Reply Private Reply Replies (0) Message Board
Warhead
From the other board:
Boiler1183
Tuesday, October 08, 2013 6:33:40 PM
Re: slazenger7 post# 63211
Post # of 63278
Here are the facts every investor should be considering. This needs to be read and understood by anyone investing in Solos.

As to my accreditation, I personally work for a niche supplier to the aerospace and power-generation industries, and will speak analogously from my experience and knowledge to debunk some of the unnecessary arguments being used to propagate doubt and fear about Solos' business approach. I will present nothing but general knowledge, experience, and facts, and allow the reader to draw their own conclusions.

I have seen the rhetorical question posed several times about how the ISO 13485:2003 and CE mark could possibly improve Solos' market penetration in selling Endoscopic equipment. Such a question shows a clear disconnect from a supplier-based environment. My company makes one specific type of product, and as a supplier you have intermittent customers, your mom-and-pop machine shops and aftermarket consumers, that have "low-standards," if you will. These customers scrape together sales that account for a tiny fraction of our revenue in a given year, on the order of a few hundred thousand dollars . Almost all small suppliers start off in such a market, using their limited manufacturing capabilities and lack of proper certification to please the one-off customers - the research labs and student hospitals, if you will. Sometimes this is enough to grow your capacity to a point where you can afford the next big step, and sometimes additional capital is raised through investors, but one truth remains: the real money is made through the real customers - the multi-billion dollar corporations that account for the majority of the market. Unfortunately, the real customers have higher standards than the one-off customers, and to even be considered as a supplier to the big customers, you must meet certain international standards for quality.

This is the fact that many fail to consider. Being certified to the industry-standard ISO certifications is not a bragging right - it is a REQUIREMENT to even be considered as a supplier when it comes to the big customers. For my company, our millions are made through the aerospace giants of the world, all who require us to be ISO 9001:2008 certified. Receiving and maintaining such certification is incredibly costly and tedious, but without it we would literally not even be considered in the running with the customers who keep our lights on.

What is more, the large customers for specialized products and devices are generally required to diversify their supplier base as to limit their supplier-end risk as a business and to ensure competitive pricing from suppliers. This push for diversification is ongoing and persistent, beneficial both to the customers and the suppliers.

To answer the rhetorical question of "how will this certification impact their ability to penetrate the $100 billion domestic market", my answer is simple. The real customers of any industry, whether it be aerospace, medical, or otherwise, demand certain International Standards for quality (see "ISO"). Such accreditation offers enormous opportunity to capture market share for the exact reasons mentioned. This is not my opinion, this is fact. My company of a few dozen employees thrives in a competitive niche market specifically because we achieved and maintained the Industry Standard quality requirements and, in turn, won sales contracts with the industry giants that account for millions a year in revenue.

As to anyone who doubts Solos' business approach of using their meager revenue and stock offerings to obtain the capital and quality of business necessary to achieve international quality standards, I pose the following question. What business owner with a competent understanding of their market would not strive to meet the requirements necessary to secure the revenue that is offered by the high-end customers?

Just as I have done by investing in Solos' potential, Solos has invested in their potential to secure a portion of the medical device market by achieving the qualifications necessary to supply to the industry giants. Call it whatever you want, this is what is unfolding, and I for one could not agree more with their approach. 



If you still have access to that board, Hogan's response must be marked as a violation of TOS.

CYduct Diagnostics Inc. (CYDX) Stock Research Links

CYDX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 15

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Midea’s SC26 Cooling Pitch Targets AI Build Delays

Updated Category News Views 80

Heat is the uninvited partner in every AI build, and Midea is making a sensible argument that nobody gets paid for racks sitting idle while piping crews wrestle with a complicated cooling plant. At SC26 in Chicago, held November 17 through 19, the company made its North American debut for a modular prefabricated AI data-center cooling setup built around a magnetic coolant...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 113

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 36

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 215

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 119

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 14

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
VIGGO’s Mix1Pro Tests Practical Commercial Cleaning

Updated Category News Views 61

A cleaning robot earns its keep in the ugly corners, not under convention-center lights. VIGGO used the ISSA Show North America gathering in Las Vegas, held November 17–19, 2026, to introduce the Mix1Pro, a compact commercial machine aimed at indoor facilities below 53,800 square feet. That target matters. Smaller, messier sites are where autonomy can look terrific on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Enzyme Inhibitor Market Growth Forecast: US$ 5.9 Billion

Updated Category News Views 125

The Future of the Enzyme Inhibitor Market The enzyme inhibitor market is positioned for significant growth, projected to reach US$ 5.9 billion by 2034, following an estimated rise from US$ 2.8 billion in 2023. This impressive growth is driven by a compound annual growth rate (CAGR) of 7.1% over the next decade. Enzyme inhibitors, particularly angiotensin-converting enzyme...

Continue Reading
Li-Cycle Announces $15 Million Public Offering Insights

Updated Category News Views 213

Li-Cycle Announces $15 Million Underwritten Public Offering Li-Cycle Holdings Corp. (NYSE: LICY), a recognized leader in lithium-ion battery resource recovery, has unveiled details about its recent public offering. This strategically planned offering is projected to raise approximately $15 million for the company, providing essential funding to support its ongoing and...

Continue Reading
Investors Encouraged to Join Edwards Lifesciences Case

Updated Category News Views 117

Investors Encouraged to Join Edwards Lifesciences Case In recent developments, the Rosen Law Firm, a dedicated advocate for investor rights, is reaching out to individuals who purchased securities of Edwards Lifesciences Corporation (NYSE: EW) during a specified time frame. This outreach aims to inform these investors about their rights and potential avenues to seek...

Continue Reading
AtlasNova's $2.3M Funding to Transform Small Business Automation

Updated Category News Views 318

AtlasNova Secures $2.3 Million for Small Business Automation With the latest funding, AtlasNova is dedicated to enhancing the operations of small businesses, helping them leverage efficiencies that typically only larger corporations enjoy. Unlocking Potential Through Intelligent Automation AtlasNova has successfully secured a seed round of $2.3 million, enabling them to...

Continue Reading
Congressman Questions SEC's 'Digital Asset Security' Definition

Updated Category News Views 196

Congressman Ritchie Torres Questions SEC's Use of Terminology Representative Ritchie Torres, a Democratic representative from New York, has recently shared his concerns about the phrase "digital asset security" as used by the U.S. Securities and Exchange Commission (SEC). He’s particularly interested in the legal basis and origins of this term. Congressional Dialogue...

Continue Reading